AMR Stakeholder Profile
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
Focus area/active in: Human Health, Therapeutics, Diagnostics
Company/Organisation type: Accelerator | Finance | Investor
CARB-X is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, the Wellcome Trust, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Bill & Melinda Gates Foundation, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). CARB-X is investing up to $500 million from 2016-2021 to support innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics. The CARB-X portfolio is focused on the greatest bacterial threats to human health, primarily those threats identified as “Urgent” and “Serious” in the 2019 CDC Threat Assessments or “Critical” or “High” in the 2017 Global Priority Pathogen List published by the WHO. CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X is headquartered at Boston University School of Law.
Would you like to meet CARB-X virtually during the AMR Conference week?
Get in touch!
Deputy Executive Director
Please fill out the form below to get in touch with us.